---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-011587"
form_type: "8-K"
ticker: "CERO"
cik: "0001870404"
company_name: "CERO THERAPEUTICS HOLDINGS, INC."
filed_at: "2026-02-03T23:59:59+00:00"
generated_at: "2026-05-16T05:24:13.976830+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.95
calibrated_materiality_score: 0.95
confidence: "high"
source: SEC EDGAR
---

# Nasdaq Listing Council affirms delisting of CERo Therapeutics securities

## Summary
- On Jan 29, 2026, the Nasdaq Listing and Hearing Review Council upheld the Panel's Oct 29, 2025 decision to delist CERo common stock and warrants.
- Delisting and trading suspension originally effective Oct 31, 2025; the Council's affirmance makes the delisting final.
- Common stock ticker CERO and warrants ticker CEROW will no longer trade on Nasdaq.

## SEC filing metadata
- accession: 0001213900-26-011587
- form_type: 8-K
- ticker: CERO
- cik: 0001870404
- company_name: CERO THERAPEUTICS HOLDINGS, INC.
- filed_at: 2026-02-03T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.95
- calibrated_materiality_score: 0.95
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1870404/000121390026011587/0001213900-26-011587-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1870404/000121390026011587/ea0274896-8k_cero.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-011587
- JSON: https://secwatch.observer/filing/0001213900-26-011587.json
- Plain text: https://secwatch.observer/filing/0001213900-26-011587.txt

## Key facts
- Listing & Compliance Notices
  CERO THERAPEUTICS HOLDINGS, INC. received a nasdaq delisting notice notice regarding other.
  - Exchange: nasdaq
  - Notice: delisting notice
  source text: January 29, 2026, after considering the written record in this matter, the Council issued its decision affirming the Panel’s decision to delist the Company’s securities from Nasdaq. 1 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: February 3, 2026 CERO THERAPEUTICS HOLDINGS, INC. By: /s/ Chris Ehrlich Name: Chris Ehrlich Title: Chief Executive Officer 2
  evidence_url: https://www.sec.gov/Archives/edgar/data/1870404/000121390026011587/0001213900-26-011587-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.